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Japan. In this study, we conducted an economic evaluation of a universal infant
hepatitis B vaccination compared with the current selective strategy of vaccinating
high-risk infants. METHODS: A cost-effectiveness analysis was conducted using a
Markov model. The state transition process was defined as a series of 9 states
including susceptible, immune, acute hepatitis, fulminant hepatitis, asymptom-
atic carrier, chronic hepatitis, liver cirrhosis, hepatocellular carcinoma and death.
All data on cost, epidemiology and utility were derived from official statistics,
published literatures and expert opinion. The incremental cost-effectiveness ratio
(ICER) per quality-adjusted life year gained and life-year gained were calculated at
a 3% discount rate. The analysis was performed from payer’s perspective and time
horizon was set to 100 years. One-way sensitivity analysis was undertaken. All
parameters were projected to the population of 2009 birth cohort, 1.078 million.
RESULTS: By introducing the universal hepatitis B vaccination, 1,507 patients and
197 deaths caused by HBV related liver diseases were expected to be prevented.
Cost of medical care was saved 770 million yen, but the cost of vaccination was 1.77
billion yen. Estimated ICERs were 18,300,515 yen/QALY and 20,093,520 yen/LYG.
When the cost of vaccination was 5,600 yen(1,868 yen per dose), ICER was 5,000,000
yen/QALY.CONCLUSIONS:At a cost of 5,600 yen(1,868 yen per dose) of vaccination,
universal hepatitis B policy was considered to be cost- effective in Japan. In hepa-
titis B, regional differences of genotype were well-known and affected the sequel of
hepatitis B related diseases. Because most of the epidemiological data employed in
this study were derived from foreign literatures, we try to replace then into esti-
mated local data. This study was partially supported by the grant of Japanese
Ministry of Health, Labor and Welfare (Research on Applying Health Technology).
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OBJECTIVES: Anaphylaxis is a severe life threatening acute event that can have a
number of triggers. Specialist services are believed to be important in preventing
recurrence and current lack of referral might mean high recurrence rates and
unnecessary cost. Also, lack of timely and correct use of adrenaline injectors might
lead to significant excess mortality. The study objective was therefore to assess the
cost effectiveness of specialist service versus standard care with or without pre-
scription of adrenaline injectors. METHODS: A Markov model validated by clinical
experts was constructed, which modeled anaphylaxis according to trigger, either
food, drug, insect or idiopathic. Anaphylaxis mortality was modeled as a function
of time to die and time for emergency response. Probabilistic sensitivity analysis on
key parameters was performed. RESULTS: Standard care with injectors was dom-
inated by specialist service with or without injectors. Specialist service with no
injectors would be cost effective if the threshold for a Quality Adjusted Life Year
was greater than about £740 and with injectors would be cost effective if the
threshold was greater than £1800. These results were robust to all sensitivity anal-
yses except at relatively extreme values of a small number of parameters.
CONCLUSIONS: This is the first study to address the cost effectiveness of specialist
service or adrenaline injectors in anaphylaxis. The results showed that specialist
service with adrenaline injectors was cost effective at a threshold of £20,000 per
Quality Adjusted Life Year. More well designed prospective studies on the effec-
tiveness of specialist services are needed to confirm these findings.
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OBJECTIVES: Participation in coronary heart disease (CHD) secondary prevention
programs is low, therefore an innovative program is needed to meet this treatment
gap. As a secondary aim within a large trial, the current study evaluated cost-
effectiveness of a telephone-delivered secondary prevention program for myocar-
dial infarction patients compared to usual care. METHODS: A total of 430 adult
myocardial infarction patients were randomised to a six-month CHD secondary
prevention ‘health coaching’ intervention or usual care condition. Primary out-
come variables were health-related quality of life (SF-36) and physical activity (Ac-
tive Australia Survey). Data were collected at baseline, 6 months (post-interven-
tion) and 12 months (6 months post-intervention). A secondary cost-effectiveness
analysis was conducted. Health utility (SF-6D) and health care utilisation data were
collected using self-reported (GP, specialist, other health professionals, health ser-
vices, and medication) and claims data (hospitalisation rates). Multiple imputation
techniques were applied to adjust for missing data. Intervention effects are pre-
sented as mean difference (95% CI), p value. RESULTS: Improvements in health
status (SF-6D) were observed in both groups, with no significant difference between
the groups at 6 [0.012 (-0.016, 0.041), p0.372] or 12 months [0.011 (-0.028, 0.051)
p0.738]. Patients in the health coaching group were significantly more often ad-
mitted to hospital due to causes not related to cardiovascular disease (p0.042).
The overall cost for the health coaching group was higher ($10,574 vs. $8,534,
p0.021), mainly due to higher hospitalisation costs ($6,841 vs. $4,984, p0.036).
The incremental cost-effectiveness ratio was $85,423 per QALY. CONCLUSIONS:
ProActive Heart is not a cost-effective intervention compared to usual care. There
was no intervention effect on SF-6D at 6 or 12 months and it resulted in signifi-
cantly increased costs. This higher cost may in the future eventuate in cost savings,
as patients are better monitored and health problems may be identified at an
earlier stage resulting in better health outcomes.
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OBJECTIVES: To assess the cost-effectiveness of rotigotine transdermal patch rel-
ative to placebo and oral dopamine agonists (ropinirole and pramipexole) in the
treatment of moderate-to-severe idiopathic restless legs syndrome (RLS) from the
perspective of National Health Service (NHS) Scotland. METHODS: A cost-utility
analysis was conducted using a decision tree in order to measure the cost per
quality-adjusted life-year (QALY) gained resulting from the treatment of moderate-
to-severe idiopathic RLS in 2008. Clinical, safety and quality of life data were ex-
tracted from the literature. The decision analytic model was run for a 1-year time
horizon in the base-case analysis. The model included direct medical costs, aug-
mentation rate and the most common adverse events. Sensitivity analyses as-
sessed the effect of varying the time horizon to 9 months, 2 and 5 years. An annual
discount rate of 3.5% was applied to costs and benefits for analysis beyond 1 year.
RESULTS: Over a 1-year period, treating patients with rotigotine would result in a
total cost of £1658 per patient as compared with £606, £1152 and £1055 for placebo,
ropinirole and pramipexole respectively. Treatment with rotigotine resulted in
0.842 QALYs gained compared with 0.691 for placebo, 0.753 for ropinirole and 0.780
for pramipexole. The cost per QALY gained for rotigotine was £6990 versus placebo,
£5725 versus ropinirole and £9729 versus pramipexole. Probabilistic sensitivity
analysis has shown that the probability of rotigotine being cost-effective compared
with placebo, ropinirole and pramipexole is greater than 0.90 at a willingness to pay
threshold of £13,000. At a threshold of £20,000, the probability of rotigotine being
more cost-effective is close to 1 versus placebo and ropinirole and 0.93 versus
pramipexole. CONCLUSIONS: Rotigotine transdermal patch was shown to be a
cost-effective treatment in patients with moderate-to-severe restless legs syn-
drome from the payer’s perspective (NHS Scotland).
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OBJECTIVES: To evaluate the cost-effectiveness of tolvaptan for hypervolemic or
euvolemic hyponatremia in South Korea. METHODS: A decision tree was con-
structed to assess the clinical and economic impact over 30 days from restricted
societal perspective. A competitor was supportive care. The result was presented
as the incremental cost per QALY gained. We supposed that patients would move
to 3 different serum sodium levels; normonatremia (135mEq/L), mild hyponatre-
mia (130-135mEq/L), marked hyponatremia(130 mEq/L) after 4 days treatment.
Each level had three states; discharge, continuing hospitalization and death. Ac-
cording to serum sodium level, Patients had difference their length of hospital stay.
Uncertainty was explored with deterministic sensitivity analysis. RESULTS: The
analysis showed that cost of tolvaptan was 1,358,370 KRW and supportive care was
1,396,092 KRW. The use of tolvaptan reduced 37,722 KRW for supportive care.
QALYs were 0.047203, 0.042146 (tolvaptan, supportive care, respectively). Tolvap-
tan had 0.00506 QALYs higher. Cost-effectiveness analysis represented tolvaptan
was dominant. The deterministic sensitivity analysis for uncertain parameters
demonstrated that this analysis results were robust. CONCLUSIONS: Tolvaptan
was cost-effective for hyponatremia in comparison with supportive care. The first
medicine as oral vasopressin receptor antagonist, tolvaptan could increase pa-
tients’ quality of life for hyponatremia in Korean population.
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OBJECTIVES: Estimation of indirect and selected direct costs of hypoglycaemia in
patients with type 1 and type 2 diabetes in Poland. METHODS: The study was
conducted at 4 Polish diabetes centres- 2 urban and 2 suburban. Anonymous ques-
tionnaire comprising 35 questions was used in direct interviews. Data were anal-
ysed in a population of 180 patients with diagnosed diabetes who experienced
severe (requiring third party support) or/ and non-severe hypoglycaemia during
last year. Indirect costs were estimated using a human capital approach based on
lost Gross Domestic Product (GDP) and lost gross earnings. Additional estimations
of direct costs, which could be attributed to hypoglycaemic event, were based on
used medical resources and their unit prices. RESULTS: There were on average 0.16
episodes of severe and 4.66 episodes of non- severe hypoglycaemia per patient in
the recall period (1month). An average total monthly cost of severe hypoglycaemia
was 699.77 EUR, with hospitalisation being a main cost driver, and 40 EUR in the
case of a non-severe episode. 23% of the studied population was professionally
active. A total average time lost was equal to 3.85 hours, which in Polish conditions
gave an absenteeism cost per month of 16.27 EUR (GDP lost) and 16.99 EUR (lost
earnings) per person per month. 52.38% of employed patients reported reduced
productivity while at work (presenteism). Its value was estimated at the level of
14.88 EUR and 15.53 EUR per patient per episode according to GDP and earnings lost
respectively. Indirect costs related to sick-leaves and hospitalisations in working-
age population were not reported in the study. CONCLUSIONS: Hypoglycaemic
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